Why the study?
Does next-generation sequencing using a targeted gene panel identify causative mutations in patients with malignant hyperthermia?
Does next-generation sequencing using a targeted gene panel identify causative mutations in patients with malignant hyperthermia?
Answers are grounded in this paper and cite their sources.
Next-generation sequencing with a targeted gene panel is convenient for identifying RYR1 variants in malignant hyperthermia, but variant interpretation remains challenging due to phenotypic variability.
Malignant hyperthermia (MH)-related mutations have been identified in the ryanodine receptor type 1 gene (RYR1) and in the dihydropyridine gene (CACNA1S), but about half of the patients do not have causative mutations in these genes. We wanted to study the contribution of other muscle genes to the RYR1 phenotypes. We designed a gene panel for sequence enrichment targeting 64 genes of proteins involved in the homeostasis of the striated muscle cell. Next-generation sequencing (NGS) resulted in >50,000 sequence variants which were further analyzed by software filtering criteria to identify causative variants. In four of five patients we identified previously reported RYR1 mutations while the fifth patient did not show any candidate variant in any of the genes investigated. In two patients pathogenic variants were found in other genes known to cause a muscle disorders. All but one patient carried likely benign rare polymorphisms. The NGS technique proved convenient in identifying variants in the RYR1. However, with a clinically variable phenotype-like MH, the pre-selection of genes poses problems in variant interpretation.
No takes yet. Share an insight, caveat, or question.
Broman et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: